Related Experiment Video
Updated: Jun 7, 2025
07:16
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
13.6K
Progress in GABAA receptor agonists for insomnia disorder
Weiyi Wang1, Wanting Fu1, Hongyan Zhu1
1Department of Clinical Pharmacy, Xinhua Hospital Affiliated to Shanghai Jiaotong University Affiliated to School of Medicine, Shanghai, China.
Frontiers in Pharmacology
|November 20, 2024
Summary
New insomnia drugs target GABA-A receptors (GABAARs) for better sleep. This review covers current treatments and the new partial modulator, Dimdazenil, aiding future insomnia drug discovery.
Area of Science:
- Pharmacology
- Neuroscience
- Sleep Medicine
Background:
- Insomnia is a prevalent sleep disorder impacting daily function and health.
- Current treatments primarily target GABA-A receptors (GABAARs) at the benzodiazepine site, focusing on GABA-α1 selectivity.
- Existing drugs include benzodiazepines and non-benzodiazepines.
Purpose of the Study:
- To review the mechanisms of action for current insomnia medications.
- To summarize the clinical applications of existing insomnia drugs.
- To provide insights for developing more selective and potent insomnia treatments.
Main Methods:
- Literature review of pharmacological and clinical studies on insomnia treatments.
- Analysis of drug mechanisms targeting GABAARs, particularly GABA-α1.
- Examination of recent advancements, including partial allosteric modulators.
Main Results:
- Current insomnia drugs are positive allosteric modulators of GABAARs.
- Benzodiazepine and non-benzodiazepine drugs represent the main classes.
- Dimdazenil, a novel partial GABAAR modulator, has been approved and launched in China.
Conclusions:
- Understanding current drug mechanisms is crucial for insomnia treatment.
- Selective GABAAR modulation offers a pathway for improved insomnia therapies.
- Further research into novel ligands can lead to more effective insomnia medications.
Related Concept Videos
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
146
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
146
01:19Management of Insomnia
231
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
231
01:23Sedatives and Hypnotics: Overview
279
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
279
01:14CNS Depressants: Barbiturates and Benzodiazepines
224
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
224
01:19Sedatives and Hypnotics Drugs: Benzodiazepines
194
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
194
01:29Anxiolytic Drugs: Benzodiazepines and Buspirone
523
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
523